Recent Updates
Recently added Catalysts
Biotech Earnings Calendar
Our Biotech Earnings Calendar provides detailed earnings and forecasted estimates for covered biotech companies, featuring current EPS for informed investment decisions.
October 2026
Sun
Mon
Tue
Wed
Thu
Fri
Sat
27
28
29
30
1
AngioDynamics
1
2
Aptorum Gr
1
3
4
5
1
6
1
7
+2 More
3
8
Tilray Brands
+2 More
3
9
10
NewcelX
+1 More
2
11
12
+1 More
2
13
+2 More
3
14
1
15
1
16
17
18
19
+7 More
8
20
+5 More
6
21
1
22
+1 More
2
23
Sanofi
+3 More
4
24
25
26
+28 More
9+
27
+17 More
9+
28
+5 More
6
29
+10 More
9+
30
AbbVie
+5 More
6
31
: 2026-10-28
Previous EPS
: -3.93
Estimated EPS:
: -0.08
: 2026-10-28
Previous EPS
: 5.82
Estimated EPS:
: 2.64
: 2026-10-28
Previous EPS
: 6.04
Estimated EPS:
: 1.63
Description
: Drug: zilebesiran. Indication: Uncontrolled hypertension. Timeline: August 30, 2026. Alnylam will present a subgroup analysis from the Phase 2 KARDIA-3 trial evaluating zilebesiran in combination with a diuretic in patients with uncontrolled hypertension at ESC Congress on August 30, 2026.
: 2026-10-28
Previous EPS
: 0.45
Estimated EPS:
: 0.22
Description
: A Biologics License Application (BLA) for ADL-018 is expected to be submitted to the U.S. FDA in the fourth quarter of 2025 by Kashiv BioSciences, with Amneal holding exclusive U.S. commercialization rights.
: 2026-10-28
Previous EPS
: -6.89
Estimated EPS:
: -1.61
Description
: Results from the Phase 3 ENERGIZE-T study evaluating mitapivat will be presented in an oral session at ASH 2024.
: 2026-10-14
Previous EPS
: -1.1
Description
: Drug: Pulmazole (inhaled itraconazole). Indication: Allergic Bronchopulmonary Aspergillosis (ABPA) in asthmatics. Timeline: 4Q 2019. Phase 2 28-day proof-of-mechanism trial data readout expected in 4Q 2019 for Pulmazole, an inhaled itraconazole to treat ABPA in asthmatics. The study will assess safety, tolerability, pulmonary function (FEV1) and relevant biomarkers.
AngioDynamics
: 2026-10-01
Previous EPS
: -0.78
Estimated EPS:
: -0.09
: 2026-10-29
Previous EPS
: -13.25
Estimated EPS:
: -0.76
Description
: Data from the MARCH/MARCH-ON trials showing maralixibat's impact on growth in PFIC patients will be presented.
: 2026-10-29
Previous EPS
: -2.56
Estimated EPS:
: -0.83
Description
: Drug: CYWC628. Indication: diabetic foot ulcers. Timeline: second half of 2026. CYWC628 Phase 1/2 clinical trial in diabetic foot ulcers: Expects to report interim results in the second half of 2026.
: 2026-10-29
Previous EPS
: 1.29
Estimated EPS:
: 2.11
Description
: Drug: ENFLONSIA (clesrovimab-cfor). Indication: prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in children under two years of age at increased risk for severe RSV disease through their second RSV season. Timeline: March 22, 2027. The FDA has accepted a supplemental Biologics License Application (sBLA) for ENFLONSIA to expand its indication to include prevention of RSV lower respiratory tract disease in children under two years of age at increased risk for severe RSV disease through their second RSV season, and has set a PDUFA (target action) date of March 22, 2027.
: 2026-10-29
Previous EPS
: 3.57
Estimated EPS:
: 3.76
Description
: Drug: Telisotuzumab vedotin (Teliso‑V). Indication: Diffuse pleural mesothelioma (preclinical models). Timeline: 2026-09-14. A pre-clinical poster at WCLC 2026 will report telisotuzumab vedotin antitumor efficacy in preclinical models of diffuse pleural mesothelioma.
: 2026-10-29
Previous EPS
: 29.97
Estimated EPS:
: 8.81
Description
: Drug: LY4170156 (investigational ADC targeting FRα). Indication: platinum-resistant ovarian cancer. Timeline: October 17-21, 2025. Poster presentation of updated safety and efficacy results from the Phase 1a/1b study of LY4170156 in patients with platinum‑resistant ovarian cancer at the ESMO Annual Meeting in Berlin.
: 2026-10-29
Previous EPS
: -1.89
Estimated EPS:
: 0.44
Description
: Drug: SPN-830 apomorphine infusion device. Indication: Motor fluctuations (OFF episodes) in Parkinson's disease. Timeline: 2025-02-01. Supernus reported the SPN-830 NDA resubmission has a FDA user fee goal date (PDUFA target action date) of February 1, 2025 for the continuous treatment of motor fluctuations (OFF episodes) in Parkinson's disease.
: 2026-10-29
Previous EPS
: 4.54
Estimated EPS:
: 1.61
Description
: Drug: ide-cel. Indication: 4L+ MM. Timeline: 2021-03-27. ide-cel (BMS) has a PDUFA target action date on March 27, 2021 for its 4L+ multiple myeloma regulatory review.
: 2026-10-29
Previous EPS
: -0.28
Estimated EPS:
: -0.04
Sanofi
: 2026-10-23
Previous EPS
: 2.4
Description
: Drug: amlitelimab (SAR445229, KY1005). Indication: moderate-to-severe atopic dermatitis (AD). Timeline: H2 2026. Results from ESTUARY, a phase 3 extension study of amlitelimab evaluating Q12W maintenance dosing and longer-term safety in patients with moderate-to-severe atopic dermatitis, are anticipated in H2 2026 as reported by Sanofi.
Dr Reddy's Laboratories
: 2026-10-23
Previous EPS
: 0.59
Anbio Biotechnology
: 2026-10-23
Previous EPS
: 0.16
: 2026-10-26
Previous EPS
: -5.14
: 2026-10-26
Previous EPS
: 4.39
Estimated EPS:
: 1.03
: 2026-10-26
Previous EPS
: 0.23
Estimated EPS:
: 0.04
Description
: Drug: ZORYVE foam 0.3%. Indication: hidradenitis suppurativa. Timeline: first quarter of 2027. Arcutis continues to enroll patients in the Phase 2 proof-of-concept study of ZORYVE foam 0.3% for hidradenitis suppurativa and expects to report results and decisions on program advancement in the first quarter of 2027.
: 2026-10-26
Previous EPS
: 0.39
Estimated EPS:
: -0.01
Description
: Drug: ALKS 8700. Indication: Relapsing forms of multiple sclerosis. Timeline: first half of 2018. Initial data from EVOLVE‑MS‑2, a head‑to‑head study evaluating gastrointestinal tolerability of ALKS 8700 compared to TECFIDERA, are expected in the first half of 2018.
: 2026-10-26
Previous EPS
: -1.52
Estimated EPS:
: -0.3
: 2026-10-26
Previous EPS
: -0.71
Estimated EPS:
: 0.07
: 2026-10-26
Previous EPS
: 8.47
Estimated EPS:
: 3.04
: 2026-10-26
Previous EPS
: 6.94
Estimated EPS:
: 1.57
Description
: Drug: elagolix. Indication: uterine fibroids. Timeline: 2019. Positive Phase III ELARIS UF-I and UF-II results for elagolix in uterine fibroids will form the basis for an anticipated 2019 supplemental New Drug Application (sNDA) submission to the FDA for approval in uterine fibroids.
: 2026-10-26
Previous EPS
: 2.13
Estimated EPS:
: 1.22
: 2026-10-26
Previous EPS
: -0.46
Estimated EPS:
: -0.14
: 2026-10-26
Previous EPS
: 7.95
Estimated EPS:
: 1.78
Description
: Drug: INCB123667 (CDK2). Indication: recurrent epithelial ovarian cancer (rEOC). Timeline: October 23–27, 2026. Preliminary efficacy data from the ongoing Phase 1 trial evaluating INCB123667 in combination with bevacizumab in patients with recurrent epithelial ovarian cancer will be highlighted in a rapid oral presentation at the 2026 ESMO Congress (October 23–27, 2026).
: 2026-10-26
Previous EPS
: 42.04
Estimated EPS:
: 10.85
Description
: The U.S. FDA is expected to make a decision on the supplemental Biologics License Application (sBLA) for Dupixent in children aged 2 to 11 years with CSU by April 2026.
: 2026-10-26
Previous EPS
: -3.61
Estimated EPS:
: -0.89
Description
: Arcus plans to initiate its first Phase 3 study, PEAK-1, evaluating casdatifan in combination with cabozantinib for metastatic ccRCC patients.
: 2026-10-26
Previous EPS
: 1.4
Estimated EPS:
: 0.3
Description
: Drug: Rilonacept. Indication: Pericarditis. Timeline: November 2019. Final data from an open-label, multicenter Phase 2 clinical trial of rilonacept in a range of pericarditis populations to be presented at the American Heart Association Scientific Sessions in November 2019.
: 2026-10-26
Previous EPS
: 0.65
Estimated EPS:
: 0.45
Description
: Drug: RG1068 (synthetic human secretin). Indication: Pancreatic imaging, detection of pancreatic duct abnormalities. Timeline: 2010. Repligen expects pivotal data from its Phase 3 trial of RG1068 (synthetic human secretin) for pancreatic imaging in 2010. The ~225-patient, ~30-site study assesses RG1068 in combination with MRI versus MRI alone to improve detection of pancreatic duct abnormalities.
: 2026-10-26
Previous EPS
: -1.54
Estimated EPS:
: -0.58
: 2026-10-26
Previous EPS
: -0.06
: 2026-10-26
Previous EPS
: 0.38
Estimated EPS:
: 0.95
Description
: Drug: BMN-111. Indication: Achondroplasia. Timeline: third quarter of 2012. BioMarin expects to report results from the Phase 1 two-part, double-blind, placebo-controlled study of BMN-111 in healthy adult volunteers evaluating safety, tolerability and pharmacokinetics of single and multiple subcutaneous doses (up to 74 subjects).
: 2026-10-26
Previous EPS
: -1.28
Estimated EPS:
: -0.33
NewcelX
: 2026-10-10
KalVista Pharma
: 2026-10-10
Description
: Drug: EKTERLY (sebetralstat). Indication: Hereditary angioedema (HAE), ages 2–11. Timeline: third quarter of 2026. KalVista expects to file a U.S. New Drug Application (NDA) for EKTERLY (sebetralstat) to expand use to children aged 2–11 in the third quarter of 2026, with a launch anticipated in 2027.
: 2026-10-19
Previous EPS
: -1.2
Estimated EPS:
: 0.43
: 2026-10-19
Previous EPS
: -1.07
Estimated EPS:
: -0.28
Description
: Drug: ivonescimab (SMT112/AK112). Indication: EGFR-mutated, locally advanced or metastatic non-squamous non-small cell lung cancer previously treated with a third-generation EGFR TKI. Timeline: 2026-11-14. Summit’s BLA for ivonescimab, based on the global Phase III HARMONi trial in EGFR-mutated, locally advanced or metastatic non-squamous NSCLC after third-generation EGFR TKI, has a PDUFA goal action date of November 14, 2026.
: 2026-10-19
Previous EPS
: 8.37
Estimated EPS:
: 2.51
: 2026-10-19
Previous EPS
: 5.2
Estimated EPS:
: 1.83
: 2026-10-13
Previous EPS
: 6.68
Estimated EPS:
: 2.85
Description
: Drug: nipocalimab. Indication: systemic lupus erythematosus (SLE). Timeline: EULAR 2026 Congress in London. Late-breaking presentation of Phase 2 JASMINE study results for nipocalimab in adults with moderate-to-severe SLE, reporting sustained reduction in disease activity through Week 52 and primary endpoint achievement at Week 24, to be presented at EULAR 2026 Congress in London.
: 2026-10-13
Previous EPS
: 3.14
Estimated EPS:
: 1.28
: 2026-10-07
Previous EPS
: 2.7
Estimated EPS:
: -0.72
Description
: Drug: bexobrutideg (NX-5948). Indication: Waldenström macroglobulinemia. Timeline: 2025-06-14. Poster presentation at EHA2025 on June 14, 2025 (18:30-19:30 CEST). Title: 'Bexobrutideg (NX-5948) ... shows high clinical activity and tolerable safety in an ongoing Phase 1a/b study in patients with Waldenström macroglobulinemia' (Abstract ID: PS1883).
: 2026-10-07
Previous EPS
: -0.26
Estimated EPS:
: 0.05
AbbVie
: 2026-10-30
Previous EPS
: 3.57
Estimated EPS:
: 3.76
Description
: Allergan Aesthetics will present new data from its facial aesthetics portfolio, including efficacy and safety data for TrenibotulinumtoxinE, at the IMCAS 2026 World Congress in Paris, France.
Butterfly Network
: 2026-10-30
Previous EPS
: -0.28
Estimated EPS:
: -0.04
enVVeno Medical
: 2026-10-30
Previous EPS
: -22.63
Estimated EPS:
: -9.1
Regencell Bioscience
: 2026-10-30
Previous EPS
: 0.72
: 2026-10-30
Previous EPS
: -2.56
Estimated EPS:
: -0.83
Description
: The Phase 1/2 trial of CYWC628 for diabetic foot ulcers is scheduled to start in Q1 2026, with interim results potentially available by mid-year and topline results expected before the end of 2026.
: 2026-10-27
Previous EPS
: 0.59
Estimated EPS:
: 0.33
: 2026-10-27
Previous EPS
: -0.1
Description
: Initial Phase 1 data from injectable oxyntomodulin is expected in late 2026, with plans for the oral formulation to enter the clinic thereafter.
: 2026-10-27
Previous EPS
: -0.4
Description
: Drug: CPI-613® (devimistat). Indication: First-line Metastatic Pancreatic Cancer. Timeline: 4Q 2021. Registrational Phase 3 AVENGER 500 study of CPI-613® (devimistat) + mFOLFIRINOX vs FOLFIRINOX in first-line metastatic pancreatic adenocarcinoma (N=528). Primary endpoint OS; data readout expected in 4Q 2021.
: 2026-10-27
Previous EPS
: 0.04
Estimated EPS:
: -0.03
: 2026-10-27
Previous EPS
: -0.85
Estimated EPS:
: 0.19
: 2026-10-27
Previous EPS
: -3.4
Estimated EPS:
: -1.06
Description
: Drug: eplontersen. Indication: transthyretin-mediated amyloid cardiomyopathy (ATTR-CM). Timeline: August 28–31, 2026. Ionis and AstraZeneca will present detailed analyses, subgroup analyses and a meta-analysis of CARDIO-TTRansform Phase 3 data of eplontersen in patients with ATTR-CM at ESC Congress 2026.
: 2026-10-27
Previous EPS
: -1.11
Estimated EPS:
: -0.28
Description
: Fulcrum Therapeutics will present data on Pociredir at the 5th Global Congress on Sickle Cell Disease, which may include clinical trial results and insights into its efficacy for treating SCD.
: 2026-10-27
Previous EPS
: 8.32
Estimated EPS:
: 1.75
: 2026-10-27
Previous EPS
: -1.28
Estimated EPS:
: -0.02
Description
: Drug: Vascepa (icosapent ethyl). Indication: Adjunct to diet and exercise for adult patients with mixed dyslipidemia on optimized statin therapy with triglycerides 200-499 mg/dL (ANCHOR indication). Timeline: 2013-12-20. FDA had assigned a PDUFA action date of December 20, 2013 for Amarin’s ANCHOR sNDA seeking approval of Vascepa for the mixed dyslipidemia indication; Amarin reports FDA rescinded the ANCHOR SPA and has begun a formal appeal.
: 2026-10-27
Previous EPS
: -3.59
Estimated EPS:
: -0.59
Description
: Drug: infigratinib. Indication: Hypochondroplasia. Timeline: 2026. BridgeBio plans to share data from the Phase 3 portion of the ACCEL 2/3 study in hypochondroplasia in 2026, expanding clinical readouts for infigratinib in FGFR3-driven skeletal dysplasias.
: 2026-10-27
Previous EPS
: -3.38
Estimated EPS:
: -0.76
: 2026-10-27
Previous EPS
: -0.57
Estimated EPS:
: 0.12
Description
: The FDA has extended the PDUFA goal date for the Biologics License Application for Avance® Nerve Graft to December 5, 2025, allowing additional time for review due to a Major Amendment submission.
: 2026-10-27
Previous EPS
: -3.19
Estimated EPS:
: -0.21
Description
: The FDA has accepted Glaukos' New Drug Application (NDA) for Epioxa™, a next-generation corneal cross-linking therapy for keratoconus, a progressive eye disease that weakens the cornea. Unlike the existing Epi-off procedure, Epioxa is a non-invasive therapy that does not require removal of the corneal epithelium, potentially improving patient comfort, reducing procedure time, and shortening recovery. The NDA submission is supported by two pivotal Phase 3 trials, which met primary efficacy endpoints and demonstrated favorable safety and tolerability. If approved, Epioxa would be the first FDA-approved non-invasive corneal cross-linking drug therapy.
: 2026-10-27
Previous EPS
: 0.21
Estimated EPS:
: -0.01
: 2026-10-27
Previous EPS
: -3.45
Estimated EPS:
: -0.09
: 2026-10-20
Previous EPS
: -4.21
Estimated EPS:
: -1.27
Description
: Drug: VK2735 (VENTURE-Oral). Indication: Obesity. Timeline: Q3 2025. Viking announced positive topline results from its Phase 2 VENTURE-Oral dosing study in Q3 2025 showing statistically significant reductions in body weight (up to 12.2% at 13 weeks) with an encouraging safety and tolerability profile.
: 2026-10-20
Previous EPS
: 18.21
Estimated EPS:
: 5.72
Nurix Therapeutics
: 2026-10-08
Previous EPS
: 2.7
Estimated EPS:
: -0.72
Description
: Drug: NRX-0305. Indication: intracranial models of melanoma brain metastasis and primary glioma. Timeline: 2026-04-21. Nurix will present preclinical data on NRX-0305 showing robust efficacy in intracranial models of melanoma brain metastasis and primary glioma at the AACR 2026 Annual Meeting (April 21, 2026).
Neogen
: 2026-10-08
Previous EPS
: -0.26
Estimated EPS:
: 0.05
Aptorum Gr
: 2026-10-02
: 2026-10-05
Previous EPS
: -9.57
: 2026-10-06
Previous EPS
: 4.04
: 2026-10-12
Previous EPS
: -1.2
: 2026-10-12
Previous EPS
: -1.09